Development of technologies for evaluation of antibody response following Coronavirus Infection vs Vaccination to identify immune correlates of protection

武汉新型冠状病毒（nCoV）的出现引发了迅速开发有效医疗对策的努力，包括针对这种严重疾病的疫苗和治疗方法。然而，对动物或人类接种疫苗或nCoV感染后产生的多克隆抗体应答的了解有限。重要的是要识别和理解有合理可能预测临床获益的免疫标志物，并有助于评估疫苗和候选治疗药物，包括： I.不同的疫苗平台是否在人与动物中引发相似或不同的抗体表位库、抗体同种型、抗体亲和力和持久性？ 二.保护nCoV的相关因素是什么：总抗体与刺突蛋白内特定抗原区域的结合？抗体亲和力？抗体同种型？抗体表位多样性？ 三. nCoV疫苗接种产生的抗体的数量、质量（表位和亲和力）和持久性是否与感染后（急性和恢复期）血清中发现的抗体相似或不同？ 为了解决这些差距，我们将开发先进的技术，包括全基因组噬菌体展示文库（GFPDL）和新型冠状病毒（nCoV）的SPR，以深入分析动物模型或人类接种疫苗和nCoV感染后的免疫反应。

The emergence of the Wuhan new coronavirus (nCoV) initiated efforts to rapidly develop effective medical countermeasures including vaccines and therapeutics against this severe disease. However, there is limited knowledge on polyclonal antibody responses generated following vaccination or nCoV infection in animals or humans. It is important to identify and understand immune markers that are reasonably likely to predict clinical benefit and that can facilitate evaluation of vaccine and therapeutic candidates, including: I. Do different vaccine platforms elicit similar or different antibody epitope repertoires, antibody isotypes, antibody affinity and durability in human’s vs animals? II. What are the correlates of protection against nCoV: Total antibody binding to specific antigenic regions within spike protein? antibody affinity? antibody isotype? antibody epitope diversity? III. Is the quantity, quality (epitopes and affinity) and durability of antibodies generated by nCoV- vaccination is similar or different than those of antibodies found in post-infection (in acute and convalescent) sera? To address these gaps, we will develop advanced technologies, including whole genome phage display library (GFPDL) and SPR for the new Coronavirus (nCoV) for in-depth analysis of immune responses following vaccination and nCoV infection in animal models or humans.